2 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMORecruiting
The PLANCTON trial will investigate the effect of early intravenous OM-3 FAs on new onset organ failure and mortality in patients with predicted SAP.